pfizer_istock-458618835_no_limit_pictures--2

no_limit_pictures / iStockphoto.com

14 August 2018Americas

Medtech company backs down from Pfizer TM oppositions

Medical technology company Biocompatibles UK last week withdrew its oppositions to two trademarks applied for by Pfizer, four months after settlement negotiations.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

The doctrine of equivalents in the medtech arena

18 November 2020 The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

Successful Pfizer opposition against ‘Styriagra’ mark affirmed

3 May 2018 The EU General Court ruled in favour of Pfizer today after the company had opposed a trademark application made by Gall Pharma.

TM oppositions against Pfizer suspended amid negotiations

19 April 2018 Two trademark oppositions against Pfizer have been suspended as the parties are engaged in negotiations to settle the disputes.

More on this story

The doctrine of equivalents in the medtech arena

18 November 2020 The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

Successful Pfizer opposition against ‘Styriagra’ mark affirmed

3 May 2018 The EU General Court ruled in favour of Pfizer today after the company had opposed a trademark application made by Gall Pharma.

TM oppositions against Pfizer suspended amid negotiations

19 April 2018 Two trademark oppositions against Pfizer have been suspended as the parties are engaged in negotiations to settle the disputes.

More on this story

The doctrine of equivalents in the medtech arena

18 November 2020 The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

Successful Pfizer opposition against ‘Styriagra’ mark affirmed

3 May 2018 The EU General Court ruled in favour of Pfizer today after the company had opposed a trademark application made by Gall Pharma.

TM oppositions against Pfizer suspended amid negotiations

19 April 2018 Two trademark oppositions against Pfizer have been suspended as the parties are engaged in negotiations to settle the disputes.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB